A 2011-2012 Survey of Doctors’ Perceptions of Korean Guidelines and Empirical Treatment of Community-Acquired Pneumonia

Hye-In Kim¹, Shin-Woo Kim¹, Hyun-Ha Chang¹, Jong-Myung Lee¹, and Kyong Ran Peck²

¹Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu; ²Department of Internal Medicine, Samsung Medical Center, Seoul, Korea

Background: The causative pathogens of and prevalence of antibiotic resistance in community-acquired pneumonia (CAP) varies across countries. We evaluated the patterns of antibiotic prescriptions for adult CAP patients, and physician satisfaction with the form and content of the 2009 Korean CAP treatment guidelines.

Materials and Methods: We designed an online survey for clinical physicians who treat CAP (infectious disease specialists, pulmonologists, and other physicians). We e-mailed the online survey to physicians and gathered results from December 2011 to January 2012, and then analyzed their responses.

Results: A total of 157 physicians responded to our survey: 61 (38.9%) infectious disease specialists, 33 (21.0%) pulmonologists, and 63 (40.1%) other physicians. Two-thirds (96/157, 61.2%) had positions in tertiary and secondary hospitals; the others (61, 38.8%) worked in primary clinics (hospitals and private clinics). One hundred and eight (68.8%) were aware of the Korean CAP clinical guidelines; of these, 98 (62.4%) applied the guidelines to their practice. Among physicians using them, 86.7% (85/98) reported the guidelines to be most useful for empirical selection of antibiotics, and 75.2% (118/157) said the guidelines were useful and satisfactory. Sixty-eight (43.3%) respondents indicated that they had not used aminoglycosides as an initial empirical CAP treatment, while 51 (32.5%) had combined aminoglycosides with other antibiotics to treat patients with CAP. Seventy-three (46.5%) physicians often combined macrolides with β-lactam antibiotics for empirical treatment of CAP, and 21 (13.4%) reported using macrolide monotherapy (which is not recommended in the 2009 Korean CAP treatment guidelines) for CAP patients. The most commonly used β-lactams were third-generation cephalosporins (72, 45.9%) and ampicillin/sulbactam or amoxicillin/clavulanate (28, 17.8%).

Conclusions: Some physicians remain unaware of the 2009 Korean treatment guidelines for CAP and do not use them in clinical practice. In addition, aminoglycoside combination therapy is frequently and inappropriately used in practice. In some cases, CAP is treated with macrolide monotherapy. Thus, the Korean CAP clinical guidelines must be more aggressively and continuously publicized.

Key Words: Pneumonia, Guidelines, Antibiotics
Introduction

Community-acquired pneumonia (CAP) is a common infectious disease. Despite advances in diagnostic and treatment methods, CAP infections can still lead to death. Less than 1–5% of deaths among ambulatory patients are reportedly caused by CAP, but an average of 12% of CAP patients require hospitalization, especially the elderly or patients with underlying diseases [1]. According to the statistical yearbook released by the National Bureau of Statistics, a CAP mortality rate in Korea was 9.4 people per 100,000 in 2007, ranking first among causes of death from infections in Korea [2]. Because it may be difficult to identify CAP pathogens, the choice of antibiotic treatment is usually empirical [3]. Pathogen distribution and antibiotic resistance differ between countries, so it may be not appropriate to use the foreign guidelines for CAP therapy in Korea.

Despite availability of appropriate antibiotic therapy for CAP, mortality rates are still high; the causative pathogens and antibiotic resistance vary across countries. Thus, at the end of 2009, the Joint Committee of the Korean Society for Chemotherapy, the Korean Society of Infectious Diseases, and the Korean Academy of Tuberculosis and Respiratory Diseases published the Korean treatment guidelines for CAP [4]. These guidelines are based on CAP treatment guidelines that had been established on the basis of research data obtained from the Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) [5] over the last 10 years, as well as data on causative pathogens and antibiotic resistance in domestic CAP.

We investigated physicians’ awareness and practical application of and satisfaction with the Korean guidelines. We also

| Question                          | Frequency (%) |
|-----------------------------------|---------------|
| **Sex**                           |               |
| Male                              | 119 (75.8)    |
| Female                            | 38 (24.2)     |
| Total                             | 157 (100)     |
| **Specialty**                     |               |
| Pulmonology                       | 33 (21.0)     |
| Infectious disease                | 61 (38.9)     |
| Internal medicine except pulmonology or infectious disease | 62 (39.5)     |
| Family medicine                   | 1 (0.6)       |
| Total                             | 57 (100)      |
| **Workplace**                     |               |
| Tertiary hospital                 | 64 (40.8)     |
| Secondary hospital                | 32 (20.4)     |
| Hospital                          | 6 (3.8)       |
| Private clinic                     | 55 (35.0)     |
| Total                             | 157 (100)     |
| **Average number (monthly) of CAP outpatients this year** |               |
| None                              | 8 (5.1)       |
| 1–2 patients                      | 51 (32.5)     |
| 3–4 patients                      | 40 (25.5)     |
| 5–6 patients                      | 19 (12.1)     |
| 7–8 patients                      | 12 (7.6)      |
| More than 9 patients              | 27 (17.2)     |
| Total                             | 157 (100)     |
| **Average number of CAP inpatients this year** |               |
| None                              | 46 (29.3)     |
| 1–2 patients                      | 35 (22.3)     |
| 3–4 patients                      | 27 (17.2)     |
| 5–6 patients                      | 13 (8.3)      |
| 7–8 patients                      | 5 (3.2)       |
| More than 9 patients              | 31 (19.7)     |
| Total                             | 157 (100)     |
evaluated patterns of empirical antibiotic use for CAP treatment.

**Materials and Methods**

1. **Study population and period**
   An Internet survey was conducted for 2 weeks in December 2011 to January 2012. Respondents included doctors from tertiary and secondary hospitals, hospitals, and private clinics.

2. **Survey content**
   The survey included physician age, sex, and specialty (respiratory disease, infectious disease, internal medicine, family medicine, or general medicine) of physician. The survey focused on awareness of the CAP treatment guidelines published at the end of 2009, with questions to determine if the respondent knew the guidelines and how the guidelines were applied in clinical practice, as well as to identify the most useful guideline sections and reasons that survey respondents did not use the guidelines. The survey collected doctor opinions on CAP treatment patterns and factors leading to the decision to hospitalize CAP patients. Satisfaction with the guidelines’ format and contents and reasons for dissatisfaction were also investigated. To determine treatment patterns, the factors influencing selection of empirical antibiotics for CAP treatment, the combination with aminoglycosides, the empirical use of macrolides, and the preferred β-lactam drugs were investigated.

3. **Statistical analysis**
   The data were analyzed using SPSS Version 18.0 (SPSS Korea Data Solution Inc., Seoul, Korea). A frequency analysis and a multiple response analysis were performed on all participant responses. Chi-square tests were conducted and odds ratios calculated between respondent specializations and workplaces. All P-values were 2-tailed and $P < 0.05$ was considered statistically significant.

**Results**

1. **General respondent characteristics**
   The total response rate was 157/1,388 (11.3%); 61/149 (40.9%) were infectious disease specialists, 33/72 (45.8%) were pulmonologists, and 63/1,167 (5.4%) were other physicians. Among the 157 physicians, sixty-one (38.9%) were infectious disease specialists, 33 (21.0%) were pulmonologists, and 62 (39.5%) were internists (non-major in respiratory diseases or infectious diseases). One-hundred nineteen (75.8%) were men and 38 (24.2%), women; their mean (SD) age was 45.2 (9.5) years. Sixty-four doctors worked in tertiary hospitals (40.8%) and 32 (20.4%) in secondary hospitals. The respondents’ demographic characteristics are summarized in Table 1.

2. **Compliance and satisfaction with the Korean CAP treatment guidelines**
   To the question, “Did you know that the Korean CAP clinical guidelines were released in 2009?” 108 (68.8%) answered “I know” and 43 (27.4%) “I did not know” (Table 2). To “Do you

| Question                                                                 | Frequency (%) |
|-------------------------------------------------------------------------|---------------|
| Did you know that the Korean CAP clinical guidelines were released in 2009? |                |
| Yes, I know                                                             | 108 (68.8)    |
| No, I did not know                                                       | 43 (27.4)     |
| No response                                                             | 6 (3.8)       |
| Total                                                                   | 157 (100)     |
| How did you learn about the CAP clinical guidelines? (multiple choices) |                |
| Online article                                                          | 79 (38.9)     |
| Offline article                                                         | 22 (10.8)     |
| Conference, symposium                                                    | 55 (27.1)     |
| Internet classes                                                        | 3 (1.5)       |
| Others (Society of Infectious Diseases homepage, during practice as an attending resident, education programs) | 4 (2.0) |
| This survey                                                             | 40 (19.7)     |
| Total                                                                   | 203 (100)     |

CAP, community-acquired pneumonia.
98 (62.4%) said “Yes” and 53 (33.8%) said “No” (Table 3). Among those who answered “Yes, “ to “Which section is most useful?, “ the most common answer was “Initial empirical anti-\text{b}iotic treatment” (85/98, 86.7%) (Table 3). To “ Are the contents of the guidelines satisfactory?, “ 66 (42.0%) answered “Yes, “ 48 (30.6%) answered “Not good but not bad, “ and 4 (2.5%) answered “Not satisfied” (Table 4). Among the respondents who said “No” to “Why are you dissatisfied? (multiple choices)?, “ 5/14 (35.7%) answered that they “do not agree with the empirical antibiotic treatment choice. “ Compliance and satisfaction with the CAP guidelines are summarized in Tables 2, 3, and 4.

### 3. Status of and opinions on CAP treatment patterns

To the question “What influences your choice of empirical antibiotics for CAP patients?” (multiple choices), 92/357 (25.8%) answered “Korean CAP clinical guidelines for adults,“ 74 (20.7%) answered “IDSA/ATS guidelines,” 66 (18.5%) answered “Health insurance review standards for CAP,” and 61 (17.1%) answered “Antibiotic-related complications and handiness” (Table 5). To the question “Do you use aminoglycosides for empirical treatment of CAP?, “ 7 (9.5%) answered “Yes, “ 5 (6.7%) answered “No, “ and 6 (8.0%) answered “Not satisfied.” Compliance and satisfaction with the CAP guidelines are summarized in Tables 2, 3, and 4.

| Question | Frequency (%) |
|----------|---------------|
| Do you use the 2009 Korean CAP treatment guidelines in practice? | Yes 98 (62.4), No 53 (33.8), No response 6 (3.8), Total 157 (100) |
| If you answered “Yes,” which section do you find most useful? | Initial empirical antibiotic treatment 85 (86.7), No response 2 (2.0), Total 98 (100) |
| If you answered “No,” what is the main reason for not referring to the guidelines? | Not different from textbooks 3 (5.7), Similar to foreign guidelines 9 (17.0), Not as reliable because of insufficient domestic references 2 (3.8), Does not consider clinical practice situations 5 (9.4), Not concise enough 1 (1.9), Did not know it existed but willing to refer to it in the future 7 (13.2), Did not know it existed and have no intention to use it in the future 3 (5.7), No response 22 (41.5), Total 53 (100) |
| If you answered “No,” which reference do you use other than the Korean guidelines? | IDSA and ATS treatment guidelines (2007) 19 (61.3), European guidelines 1 (3.2), Others (insurance benefit standard, 1) 4 (12.9), Do not refer to foreign guidelines 7 (22.6), Total 31 (100) |
To “What β-lactam drugs do you select for empirical treatment of CAP?,” 72/157 (45.9%) responded “Third-generation cephalosporins,” 28 (17.8%) responded “Ampicillin/sulbactam or amoxicillin/clavulanate,” 6 (3.8%) responded “Not at all,” another 6 (3.8%) responded “Second-generation cephalosporins,” and 4 (2.5%) responded “First-generation cephalosporin” (Table 6). The status of and opinions on the treatment of CAP are summarized in Table 5 and Table 6.

4. Opinions on the determination of the need to hospitalize CAP patients

To “Do you use objective criteria to determine the need for hospital admission of CAP patients?,” 81/157 (51.6%) replied “I use clinical judgment rather than objective standards,” 25 (15.9%) replied “I use CURB-65,” and 9 replied (5.7%) “I use the Pneumonia Severity Index” (Table 7). These results are summarized in Table 7.

5. Responses to the CAP treatment guidelines according to specialty

To the question “Did you know that the Korean CAP guidelines were released in 2009?,” 85/90 (94.4%) of the pulmonologists and infectious disease specialists answered “I know” and 5 (5.6%) answered “I do not know”; among other physicians, 23/61 (37.7%) answered “I know” and 38 (62.3%) “I do not know.” The awareness of the CAP treatment guidelines among pulmonologists and infectious disease specialists was higher than in other physicians (odds ratio [OR]: 28.1, 95% confi-
### Table 5. Status of and opinions on the treatment of community-acquired pneumonia (I)

| Question                                                                 | Frequency (%) |
|--------------------------------------------------------------------------|---------------|
| What influences your choice of empirical antibiotics for CAP patients?  |               |
| (multiple choices)                                                       |               |
| Do not refer to any guidelines                                            | 5 (1.4)       |
| Korean CAP clinical guidelines for adults                                 | 92 (25.8)     |
| IDSA/ATS guidelines                                                      | 74 (20.7)     |
| Textbook recommendation                                                  | 43 (12.0)     |
| Antibiotic-related complication and handiness                            | 61 (17.1)     |
| Health insurance review standards for CAP                                 | 66 (18.5)     |
| Cost                                                                     | 16 (4.5)      |
| Total                                                                    | 357 (100.0)   |
| Do you use aminoglycosides for empirical treatment of CAP? (for         |               |
| inpatients or outpatients)                                               |               |
| Never                                                                    | 68 (43.3)     |
| When infection with GNB, including *Pseudomonas* infection, is likely     | 23 (14.6)     |
| When GNB, including *Pseudomonas*, is cultured in the sputum or blood    | 9 (5.7)       |
| Empirically combined when severe infection is likely                     | 16 (10.2)     |
| For almost all cases, since it is known to have some benefits from       | 3 (1.9)       |
| experience                                                               |               |
| No response                                                              | 38 (24.2)     |
| Total                                                                    | 157 (100.0)   |

CAP, community-acquired pneumonia; IDSA, Infectious Diseases Society of America; ATS, American Thoracic Society; GNB, gram-negative bacilli.

### Table 6. Status of and opinions on the treatment of community-acquired pneumonia (II)

| Question                                                                 | Frequency (%) |
|--------------------------------------------------------------------------|---------------|
| Do you use macrolides for empirical treatment of CAP? (for               |               |
| inpatients or outpatients)                                               |               |
| Not at all                                                               | 6 (3.8)       |
| Macrolides only                                                          | 6 (3.8)       |
| Macrolides only for mild pneumonia                                       | 15 (9.6)      |
| Combined with β-lactams (penicillins and cephalosporins)                 | 73 (46.5)     |
| β-lactams (penicillins and cephalosporins) (not combined with            | 7 (4.5)       |
| macrolides)                                                              |               |
| Combined empirically if severe CAP is likely                             | 10 (6.4)      |
| Others (combined with β-lactams, 1; when mycoplasma pneumonia is         | 2 (1.3)       |
| likely, 1)                                                               |               |
| No response                                                              | 38 (24.2)     |
| Total                                                                    | 157 (100.0)   |
| How do you select β-lactam drugs in the empirical treatment of CAP?     |               |
| (Intravenous or oral)                                                    |               |
| Not at all                                                               | 6 (3.8)       |
| First-generation cephalosporin                                           | 4 (2.5)       |
| Second-generation cephalosporin                                          | 6 (3.8)       |
| Third-generation cephalosporin                                           | 72 (45.9)     |
| Third-generation cephalosporin which have effect on *Pseudomonas*        | 2 (1.3)       |
| Ampicillin or amoxicillin                                                | 1 (0.6)       |
| Ampicillin/sulbactam or amoxicillin/clavulanate                          | 28 (17.8)     |
| *Pseudomonas* effective penicillins (e.g., piperacillin/tazobactam, etc.)| 0 (0)         |
| Carbapenem (imipenem, meropenem, etc.)                                   | 0 (0)         |
| No response                                                              | 38 (24.2)     |
| Total                                                                    | 157 (100.0)   |

CAP, community-acquired pneumonia.
dence interval [CI]: 9.9 to 79.5, P-value < 0.001). To “Do you use the 2009 Korean CAP treatment guidelines in practice?,” 67/90 (74.4%) pulmonologists and infectious disease specialists answered “Yes” and 23 (25.6%) answered “No”; among other physicians, 31/61 (50.8%) answered “Yes” and 30 (49.2%) “No.” The frequency CAP treatment guideline use in clinical practice was also higher among pulmonologists and infectious disease specialists than among other physicians (OR: 2.8, 95% CI: 1.4 to 5.6, P-value = 0.003). Six of 76 (7.9%) pulmonologists and infectious disease specialists, and 15 of 43 (34.9%) other physicians reported using macrolide monotherapy for CAP treatment. To “What β-lactam drugs do you use to empirically treat CAP?,” “Third-generation cephalosporins” was the most common answer (58/76, 76.3%) in pulmonologists and infectious disease specialists; “Ampicillin/sulbactam or amoxicillin/clavulanate” was the most common answer (16/43, 37.2%) in the other physicians. To “Do you use objective criteria to determine the need for hospital admission of CAP patients?” Table 7. Use of admission criteria for community-acquired pneumonia

| Question                                                                 | Pulmonologists and infectious disease specialists | Other physicians | OR (95% CI) | P-value |
|--------------------------------------------------------------------------|--------------------------------------------------|------------------|-------------|---------|
| Do you use objective criteria to determine the need for hospital         | Pneumonia Severity Index                         | 9 (5.7)          |             |         |
| admission of CAP patients?                                               | CURB-65                                          | 25 (15.9)        |             |         |
|                                                                          | CRB-65                                           | 2 (1.3)          |             |         |
|                                                                          | Clinical judgment rather than objective standards| 81 (51.6)        |             |         |
|                                                                          | Did not know of objective standards until now,    | 2 (1.3)          |             |         |
|                                                                          | and willing to refer to them in the future       |                  |             |         |
|                                                                          | No response                                      | 38 (24.2)        |             |         |
| Total                                                                    |                                                  | 157 (100.0)      |             |         |

CAP, community-acquired pneumonia; CURB-65, Confusion, Urea > 7 mmol/L, Respiratory rate > 30/min, Low Blood pressure (diastolic blood pressure [DBP] < 60 mmHg or systolic blood pressure [SBP] < 90 mmHg and age ≥ 65 years; CRB-65, does not include urea.

Table 8. Responses to the CAP treatment guidelines according to specialty (I)

| Question                                                                 | Frequency (%) | Pulmonologists and infectious disease specialists | Other physicians | OR (95% CI) | P-value |
|--------------------------------------------------------------------------|---------------|--------------------------------------------------|------------------|-------------|---------|
| Did you know that the Korean CAP clinical guidelines were released in     |               |                                                  |                  |             |         |
| 2009?                                                                    |               | Yes, I know                                       | 85/90 (94.4)     | 23/61 (37.7)| 28.1 (9.9 to 79.5) | < 0.001 |
|                                                                          |               | No, I did not know                                 | 5/90 (5.6)       | 38/61 (62.3)| -       |         |
| Do you use the 2009 Korean CAP treatment guidelines in practice?         |               | Yes                                               | 67/90 (74.4)     | 31/61 (50.8)| 2.8 (1.4 to 5.6) | 0.003  |
|                                                                          |               | No                                                | 23/90 (25.6)     | 30/61 (49.2)| -       |         |
| Do you use macrolides for empirical treatment of CAP? (for inpatients or  |               | Not at all                                         | 1/76 (1.3)       | 5/43 (11.6)| -       |         |
| outpatients)                                                             |               | Macrolides only                                   | 2/76 (2.6)       | 4/43 (9.3) | -       |         |
|                                                                          |               | Macrolides only for mild pneumonia                | 4/76 (5.3)       | 11/43 (25.6)| -       |         |
|                                                                          |               | Combined with β-lactams (penicillins and           | 59/76 (77.6)     | 14/43 (32.6)| -       |         |
|                                                                          |               | cephalosporins)                                   |                  |             |         |
|                                                                          |               | β-lactams (penicillins and cephalosporins) (not   | 2/76 (2.6)       | 5/43 (11.6)| -       |         |
|                                                                          |               | combined with macrolides)                         |                  |             |         |
|                                                                          |               | Combined empirically if severe CAP is likely      | 7/76 (9.2)       | 3/43 (7.0) | -       |         |
|                                                                          |               | Others (combined with β-lactams)                  | 1/76 (1.3)       | 1/43 (2.3) | -       |         |
|                                                                          |               | (when mycoplasma pneumonia is likely)             |                  |             |         |

CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.
sion of CAP patients?, “I use clinical judgment rather than objective standards” was the most common response (47/76, 61.8%) among pulmonologists and infectious disease specialists, as well as in other physicians (34/43, 79.1%). The responses to the CAP treatment guidelines according to specialty are summarized in Table 8 and Table 9.

| Question                                                                 | Pulmonologists and infectious disease specialists | Other physicians | OR (95% CI)          | P-value |
|--------------------------------------------------------------------------|--------------------------------------------------|------------------|----------------------|---------|
| How do you select β-lactam drugs in the empirical treatment of CAP?      | 1/76 (1.3)                                       | 5/43 (11.6)      | -                    | -       |
| intravenous or oral                                                      |                                                  |                  |                      |         |
| First-generation cephalosporin                                          | 1/76 (1.3)                                       | 3/43 (7.0)       | -                    | -       |
| Second-generation cephalosporin                                         | 2/76 (2.6)                                       | 4/43 (9.3)       | -                    | -       |
| Third-generation cephalosporin                                          | 58/76 (76.3)                                     | 14/43 (32.6)     | -                    | -       |
| Third-generation cephalosporin, which has an effect on *Pseudomonas*     | 2/76 (2.6)                                       | 0/43 (0.0)       | -                    | -       |
| Ampicillin or amoxicillin                                                | 0/76 (0.0)                                       | 1/43 (2.3)       | -                    | -       |
| Ampicillin/sublactam or amoxicillin/clavulanate                          | 12/76 (15.8)                                     | 16/43 (37.2)     | -                    | -       |
| Do you use the objective criteria to determine the need for hospital admission of CAP patients? | 7/76 (9.2)                                       | 2/43 (4.7)       | -                    | -       |
| Pneumonia Severity Index                                                |                                                  |                  |                      |         |
| CURB-65                                                                  | 20/76 (26.3)                                     | 5/43 (11.6)      | -                    | -       |
| CRB-65                                                                   | 2/76 (2.6)                                       | 0/43 (0.0)       | -                    | -       |
| Clinical judgment rather than objective standards                       | 47/76 (61.8)                                     | 34/43 (79.1)     | -                    | -       |
| Did not know objective standards until now, and willing to refer to them in the future | 0/76 (0.0)                                       | 2/43 (4.7)       | -                    | -       |

CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.
CURB-65, Confusion, Urea > 7 mmol/L, Respiratory rate > 30/min, low Blood pressure (diastolic blood pressure [DBP] < 60 mmHg or systolic blood pressure [SBP] < 90 mmHg and age ≥ 65 years); CRB-65, does not include urea.

6. Responses to the CAP treatment guidelines according to workplace

To the question “Do you know that the Korean CAP clinical guidelines were released in 2009?”, 90/93 (96.8%) of tertiary and secondary hospital doctors answered “I know,” 3 (3.2%) answered “I do not know,” while 18/58 (31.0%) of primary clinic doctors (hospitals and private clinics) answered “I know” and 40/58 (69.0%) answered “I do not know.” Awareness of the CAP treatment guidelines by tertiary and secondary hospital doctors was higher than that of the primary clinic doctors (OR: 66.7, 95% CI: 18.6 to 239.3, P-value < 0.001). To “Do you use the 2009 Korean CAP treatment guidelines in practice?”, the majority of tertiary and secondary hospital doctors answered “Yes” (72/93, 77.4%); only 21 (22.6%) said “No.” Among primary clinic doctors, 26/58 (44.8%) answered “Yes” and 32 (55.2%) “No.” Clinical use of CAP treatment guidelines was higher among tertiary and secondary hospital doctors than among primary clinic doctors (OR: 4.2, 95% CI: 2.1 to 8.6, P-value < 0.001). To “Do you use macrolides to empirically treat CAP?,” “I use macrolides only for mild pneumonia” was the most common answer of primary clinic doctors (12/38, 31.6%). To “What β-lactam drugs do you use to empirically treat CAP?, “Third-generation cephalosporins” was the most common answer among doctors of tertiary and secondary hospital doctors (66/81, 81.5%), while “ampicillin/sublactam or amoxicillin/clavulanate” was the most common answer among doctors of primary clinic doctors (17/38, 44.7%). To “Do you use objective criteria to determine the need for hospital admission of CAP patients?,” “I use clinical judgment rather than objective standards” was the most common answer among doctors of tertiary and secondary hospital doctors and primary clinic doctors (51/81, 63.0%; 30/38, 78.9%; respectively). The responses to the CAP treatment guidelines according to specialty are summarized in Table 10 and Table 11.
### Table 10. Responses to the CAP treatment guidelines according to workplace (I)

| Question                                                                 | Tertiary and secondary hospitals | Primary clinics | OR (95% CI) | P-value |
|--------------------------------------------------------------------------|----------------------------------|-----------------|-------------|---------|
| Did you know that the Korean CAP clinical guidelines were released in 2009? | Yes                              | 90/93 (96.8)    | 18/58 (31.0) | 66.7 (18.6 to 239.3) | <0.001 |
|                                                                          | No                               | 3/93 (3.2)      | 40/58 (69.0) |         |         |
| Do you use the 2009 Korean CAP treatment guidelines in practice?         | Yes                              | 72/93 (77.4)    | 26/58 (44.8) | 4.2 (2.1 to 8.6)   | <0.001 |
|                                                                          | No                               | 21/93 (22.6)    | 32/58 (55.2) |         |         |
| Do you use macrolides for empirical treatment of CAP? (for inpatients and outpatients) | Not at all                       | 0/81 (0.0)      | 6/38 (15.8)  | −       | −       |
|                                                                          | Macrolides only                  | 1/81 (1.2)      | 3/38 (7.9)   |         |         |
|                                                                          | Macrolides only for mild pneumonia | 2/81 (2.5)   | 4/38 (10.5)  |         |         |
|                                                                          | Combined with β-lactams (penicillins and cephalosporins) | 65/81 (80.2) | 8/38 (21.1)  |         |         |
|                                                                          | Beta-lactams (penicillins and cephalosporins) are used empirically and macrolides are not combined | 3/81 (3.7) | 4/38 (10.5)  |         |         |
|                                                                          | Combined empirically if severe CAP is likely | 7/81 (8.6) | 3/38 (7.9)   |         |         |
|                                                                          | Others                           | 1/81 (1.2) (combined with β-lactams) | 1/38 (2.6) (when mycoplasma pneumonia is likely) |   |   |
| CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.

### Table 11. Responses to the CAP treatment guidelines according to workplace (II)

| Question                                                                 | Tertiary and secondary hospitals | Primary clinics | OR (95% CI) | P-value |
|--------------------------------------------------------------------------|----------------------------------|-----------------|-------------|---------|
| How do you select β-lactam drugs in the empirical treatment of CAP? (intravenous or oral) | Not at all                       | 0/81 (0.0)      | 6/38 (15.8) | −       | −       |
|                                                                          | First-generation cephalosporin   | 1/81 (1.2)      | 3/38 (7.9)  |         |         |
|                                                                          | Second-generation cephalosporin  | 1/81 (1.2)      | 5/38 (13.2) |         |         |
|                                                                          | Third-generation cephalosporin   | 66/81 (81.5)    | 6/38 (15.8) |         |         |
|                                                                          | Third-generation cephalosporin, which has an effect on Pseudomonas | 2/81 (2.5) | 0/38 (0.0)  |         |         |
|                                                                          | Ampicillin or amoxicillin        | 0/81 (0.0)      | 1/38 (2.6)  |         |         |
|                                                                          | Ampicillin/sulbactam or amoxicillin/clavulanate | 11/81 (13.6) | 17/38 (44.7) |         |         |
| Do you use objective criteria to determine the need for hospital admission of CAP patients? | Pneumonia Severity Index         | 7/81 (8.6)      | 2/38 (5.3)  | −       | −       |
|                                                                          | CURB-65                          | 21/81 (25.9)    | 4/38 (10.5) |         |         |
|                                                                          | CRB-65                           | 2/81 (2.5)      | 0/38 (0.0)  |         |         |
|                                                                          | Clinical judgment rather than objective standards | 51/81 (63.0) | 30/38 (78.9) |         |         |
|                                                                          | Did not know of objective standards until now, but willing to refer to them in the future | 0/81 (0.0) | 2/38 (5.3)  |         |         |
| CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.

CURB-65, Confusion, Urea > 7 mmol/L, Respiratory rate > 30/min, low Blood pressure (diastolic blood pressure [DBP] < 60 mmHg or systolic blood pressure [SBP] < 90 mmHg and age ≥ 65 years); CRB-65, does not include urea.
Discussion

In the United States and Korea, CAP has the sixth highest mortality rate [6]. However, the distribution and resistance patterns of CAP pathogens differ among regions and countries; therefore, antimicrobial treatment of CAP also differs. The Korean CAP treatment guidelines were released at the end of 2009. They reflect the current domestic and international status of CAP causative pathogens and resistance patterns. The Korean CAP guidelines may be accepted to varying degrees by practitioners treating CAP.

Yoon et al. [7] researched antibiotic choices for patients who were hospitalized for CAP in 2004, and showed that cephalosporin was administered to 6.0% of patients, quinolone in 3.5%, β-lactam/β-lactamase inhibitors in 2.3%, and macrolides in 2.2% of patients. Empirical antibiotics for CAP treatment may have changed since this report and after the release of the new CAP treatment guidelines. We conducted our survey not only for the entire study patients’ population but also according to doctor specialization and workplace. Although the Korean CAP treatment guidelines were released a full 3 years ago, many doctors (27.4%) are still unaware of their existence. The number of other physicians and primary clinic doctors who are unaware of these guidelines was higher than that of doctors from any other specialty or workplace. In addition, fewer other physicians and primary clinic doctors use the guidelines in clinical practice. This suggests that the guidelines must be more aggressively promoted. Because online papers and official symposiums are common paths for learning about the guidelines, we should consider promoting them in more accessible and economical ways such as through the Internet or social media.

Many physicians thought that “The guidelines do not reflect the actual situation, especially on the choice of initial empirical antibiotics.” This finding is not unexpected, because the choice of antibiotics is affected by various factors such as pathogen, severity of patient disease, the doctor’s preferred antibiotics, and drug availability.

The use of β-lactam alone, combined β-lactam and macrolide, or respiratory quinolones, are recommended as empirical antibiotics for patients who do not require hospitalization. Because of their high resistance rates, tetracycline and macrolide monotherapy are not recommended treatments [4]. A secondary retrospective study was performed using the Community-acquired Pneumonia Organization CASE database (CAPO database) that was registered in Phase III clinical trials around the world. The study found that, on the basis of mortality and clinical outcomes, antibiotics that were effective for atypical pneumonia showed better results [8]. The most common response to survey questions on the content of the guidelines was dissatisfaction with the selection of initial empirical antibiotic therapy.

These responses indicate that a randomized controlled clinical trial comparing β-lactam monotherapy with combination therapy (β-lactams plus macrolides or β-lactams plus quinolone) is needed. Aminoglycosides are easily administered intramuscularly to outpatients, and anaphylaxis is rare. Some physicians still use a combination of aminoglycosides and other antibiotics as CAP therapy [9]. However, empirical aminoglycoside combination therapy should be limited to CAP cases with suspected Pseudomonas infections, and is not recommended under typical circumstances [10]. However, aminoglycoside combination therapy was often mentioned in our survey. The use of aminoglycosides as an option in treatment of pneumonia has insufficient evidence on the effectiveness and adverse events such as nephrotoxicity or ototoxicity [11, 12]. Better education and consensus on the minimization of aminoglycosides use for CAP treatment are needed for antimicrobial stewardship, patient safety, and reduction of medical costs.

This survey showed that pulmonologists, other physicians, and primary clinic doctors use macrolide therapy alone only for mild cases. Macrolide monotherapy is currently recommended for mild outpatient CAP patients by the IDSA/ATS CAP guidelines. We believe that these recommendations likely affect the high number of responses indicating monotherapy use for CAP treatment. Reported macrolide resistance rates to Streptococcus pneumoniae have reached 82.0-87.6% [4, 13-19] and resistance rates to Mycoplasma pneumoniae were similarly high; therefore, macrolide monotherapy is not recommended in the Korean CAP guidelines [20]. We need more data on the clinical significance of in vitro macrolide resistance to Mycoplasma. However, physicians should know the reasons that macrolide monotherapy is omitted from the empirical therapy recommendations in the Korean CAP guidelines.

Third-generation cephalosporins or ampicillin/sulbactam, and amoxicillin/clavulanate such as β-lactams, usually have been used for treatment of patients hospitalized with CAP [21-25]. According to our survey, very similar trends were observed in our study, yet first- or second-generation cephalosporins were often used. However, empirical antibiotic treatment of CAP with first- or second-generation cephalosporins is considered inappropriate, because pneumococcal
antibiotic resistance to cefuroxime, a typical second-generation cephalosporin [17], is 61.3%. *Haemophilus influenzae* resistance to cefuroxime and cefaclor has been reported to be 9.2% and 41.0%, respectively [26]. A large number of doctors decided to hospitalize patients on the basis of clinical judgment rather than objective criteria. This is owing to the difficulty of uniformly applying CURB-65 (Confusion, Urea > 7 mmol/L, Respiratory rate > 30/min, low Blood pressure [diastolic blood pressure [DBP] < 60 mmHg or systolic blood pressure [SBP] < 90 mmHg and age ≥ 65 years) and the Pneumonia Severity Index (PSI), severity scoring systems that are traditionally used to determine if hospitalization is required. In many circumstances, the patient’s condition, underlying diseases, and socioeconomic conditions should be considered to determine the need for hospitalization. The physician’s experience and clinical judgment are also important for making this decision. CURB-65 and CRB-65 (CRB-65 does not include urea) scores are simpler and easier to use than PSI as a CAP severity assessment tool [27], and doctors should consider its use in clinical practice to determine the need for hospitalization. The higher mortality rate of hospitalized patients compared to outpatients among low-risk patients suggests the importance of clinical judgment in addition to objective criteria [28].

As a conclusion, a large number of doctors still don’t know that the Korean CAP treatment guidelines exist even though they were released at the end of 2009. Therefore, the guidelines must be more aggressively promoted in medical society and hospitals. For some clinicians who still inappropriately use aminoglycoside as a combination therapy and macrolide monotherapy, inappropriately, we should make a strong and consistent effort to educate them and make changes in clinical practice.

### References

1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.

2. Statistics Korea. Annual report on the cause of death statistics 2007: Nation Wide. Daejeon: Statistics Korea; 2007.

3. Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med 2005;26:47-55.

4. Song HJ, Jung KS, Kang MW, Kim DJ, Pai H, Suh GY, Shim TS, Ahn JH, Ahn CM, Woo JH, Lee NY, Lee DG, Lee MS, Lee SM, Lee YS, Lee H, Chung DR. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Infect Chemother 2009;41:133-53.

5. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl 2):S27-72.

6. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-93.

7. Yoon YK, Kim EJ, Chun BC, Eom JS, Park DW, Sohn JW, Kim MJ. Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study. Respirology 2012;17:172-9.

8. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Rello J, Menendez R, Marzoratti L, Luna CM, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93.

9. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47:902-13.

10. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58.

11. Dobie RA, Black FO, Peznecker SC, Stallings VL. Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 2006;132:253-7.

12. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33:900-11.

13. Kim BN, Bae LG, Kim MN, Park SJ, Woo JH, Ryu J, Kim YS. Risk factors for penicillin resistance and mortality in Korean adults with *Streptococcus pneumoniae* bacteremia. Eur
J Clin Microbiol Infect Dis 2002;21:35-42.

14. Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, Yang Y, Li J, Chonghaeong A, Tiengrim S, Aswapokee N, Lin TY, Wu JL, Chiu CH, Lalitha MK, Thomas K, Cherian T, Perera J, Yee TT, Jamal F, Warsa UC, Van PH, Carlos CC, Shibl AM, Jacobs MR, Appelbaum PC. Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis 2001;32:1463-9.

15. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50 (Suppl S1):39-47.

16. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005;26:479-85.

17. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chonghaeong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumaraasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-7.

18. Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ, Yong D, Chong Y; KONSAR Group. High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J 2006;47:634-45.

19. Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, Lee EY, Lee JN, Chang CL. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrob Agents Chemother 2007;51:2625-7.

20. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubuakata K; Acute Respiratory Diseases Study Group. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-50.

21. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-7.

22. Cardoso MR, Nascimento-Carvalho CM, Ferrero F, Berenzin EN, Ruvinisky R, Camargos PA, Sant’anna CC, Brandileone MC, de Fátima P March M, Feris-Iglesias J, Maggi RS, Benguigui Y; CARIBE Group. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 2008;93:221-5.

23. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, Chang HH, Kim SW, Lee H, Kim YS, Oh WS, Peck KR, Chonghaeong A, Lalitha MK, Perera J, Yee TT, Jamal F, Kamarulzaman A, Carlos CC, So T; Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004;38:1570-8.

24. Hong JH, Lee HS, Jung SH, Kim GW, Eom KS, Lee JM, Jang SH, Kim DG, Hyoen IG, Lee MK, Park YB, Jung KS, Lee YK. Prevalence and clinical outcome of penicillin-resistant pneumococcal pneumonia. Tuberc Respir Dis 2003;54:295-303.

25. Hwangbo B, Yoon HI, Lee SM, Choi SH, Yoo CG, Lee CT, Kim YW, Han SK, Min KU, Kim YY, Shim YS. Clinical characteristics of pneumococcal bacteremia in adults: the effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia. Tuberc Respir Dis 1999;47:184-94.

26. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, Lee K, Lee NY. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother 2007;51:453-60.

27. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6.

28. Labarere J, Stone RA, Obrosky DS, Yealy DM, Meehan TP, Fine JM, Graff LG, Fine MJ. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis. Chest 2007;131:480-8.